RxDoctor Payments Data

Gregory Lakin

Family Medicine · Wichita, KSNPI 1003867953

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,213 of the $10,074 with a category attached, or 81.5%. Eli Lilly accounts for 87.5% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $8,828, more than ten times the $369 reported in 2019. Among family medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,074in general payments, 2019–2025

Across 28 payments — averaging $359.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$9K
  • Alkermes, Inc.$473
  • Neurocrine Biosciences, Inc.$262
  • Eisai Inc.$133
  • AstraZeneca$125
  • Jazz Pharmaceuticals Inc.$112
  • plus $156 from 8 others
$886,778in research payments, 2019–2025

Across 12 payments — averaging $73,898 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$517K
  • Astrazeneca UK Limited$331K
  • Pacira Therapeutics, Inc.$28K
  • Amarin Pharma, Inc.$11K
  • Pfizer$951

What the payments were for

  • Consulting fees$8,21382%
  • Travel & lodging$6016%
  • Food & beverage$1,22512%
  • Education$350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,074 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl296$28,381
Buprenorphine Hcl13$552
Bupropion XlBupropion Hcl13$227
Escitalopram Oxalate35$202
Buspirone Hcl22$201
Mirtazapine12$154
Clonidine Hcl15$49

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl$35$28,932309 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →